CenTrial Logo

Budesonide Suppository for Mild to Moderate Ulcerative Proctitis

by


Clinical trial finds that budesonide suppository is an effective alternative to treat ulcerative proctitis

Ulcerative proctitis is an inflammatory bowel disease (IBD) affecting the rectum, causing inflammation and ulcers in the rectum's lining. It is a form of ulcerative colitis that affects the large intestine. Symptoms of ulcerative proctitis may include rectal bleeding, diarrhea, and a constant feeling of needing a bowel movement. The exact cause of this condition is not fully understood, but it is believed to involve an abnormal immune response in the gut. Treatment options for ulcerative proctitis include medications to reduce inflammation and manage symptoms and lifestyle changes.

Clinical Trial

Researchers compared the effectiveness and safety of a new budesonide suppository (4 mg) with a commercial budesonide rectal foam (2 mg) for mild to moderate ulcerative proctitis. The trial involved 577 patients randomly assigned to receive either the budesonide suppository or foam once daily for eight weeks. The main objectives were to assess changes in clinical symptoms and mucosal healing from the start to the end of the trial.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Results

The Budesonide suppository was as effective as the foam in achieving clinical remission and mucosal healing. It was also well-tolerated by patients, with no significant differences in side effects between the two groups. Patient preferences leaned toward the suppository over the foam. The suppository also showed promising results for patients who did not respond well to mesalazine, another commonly used medication for ulcerative proctitis.

Conclusion

The budesonide suppository is a viable and safe option for treating ulcerative proctitis. It is equally effective as the foam and may offer advantages, especially for patients who prefer this treatment method or have not responded well to other medications. This study contributes valuable insights into managing ulcerative proctitis and may improve treatment options for individuals with this condition. However, further research and more extensive trials are needed to confirm these findings and establish the long-term benefits and safety of the budesonide suppository for ulcerative proctitis.
__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.